Wall Street Analysts See a 25.73 percent Upside in Entrada Therapeutics Can the Stock Really Move This High?

TRDA Stock  USD 19.89  0.06  0.30%   
About 66% of Entrada Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Entrada Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Entrada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Entrada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
The mean of analysts price targets for Entrada Therapeutics points to a 25.7 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read at zacks.com
zacks News
  

Entrada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Entrada Therapeutics Fundamental Analysis

We analyze Entrada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Entrada Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Entrada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entrada Therapeutics stock to make a market-neutral strategy. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics with similar companies.

Peers

Entrada Therapeutics Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
OPTOpthea   10.81   
0%
78.0%
VIGLVigil Neuroscience   7.39   
0%
53.0%
RLYBRallybio Corp   6.36   
0%
46.0%
CGEMCullinan Oncology   2.75   
0%
20.0%
EWTXEdgewise Therapeutics   2.48   
0%
18.0%
CNTACentessa Pharmaceuticals   1.76   
0%
12.0%
PMVPPmv Pharmaceuticals   1.25   
0%
9.0%
MOLNMolecular Partners   0.17   
1.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
5.0%
0%
PEPGPepGen   0.98   
7.0%
0%
IRONDisc Medicine   1.70   
12.0%
0%
TYRATyra Biosciences   2.00   
14.0%
0%
PHVSPharvaris   2.06   
15.0%
0%
THRDThird Harmonic   2.67   
19.0%
0%
GNTAGenenta Science   3.35   
24.0%
0%
LRMRLarimar Therapeutics   4.67   
34.0%
0%
ELYMEliem Therapeutics   5.88   
42.0%
0%

Complementary Tools for Entrada Stock analysis

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Commodity Directory
Find actively traded commodities issued by global exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories